Discontinuation of lamivudine treatment in HBeAg-negative chronic hepatitis B: a pilot study with long-term follow-up

KARAKAYA M. F. , özer s., Kalkan C., Tuzun E. A. , Caliskan A., Keskin O., ...More

ANTIVIRAL THERAPY, vol.22, no.7, pp.559-570, 2017 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 22 Issue: 7
  • Publication Date: 2017
  • Doi Number: 10.3851/imp3144
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.559-570
  • Hacettepe University Affiliated: No


Background: Finite treatment of hepatitis B e antigen (HBeAg)-negative chronic hepatitis B (CHB) with nucleoside/nucleotide analogues (NAs) is important in resource-limited countries. Outcome of treatment discontinuation in patients on long-term lamivudine (LVD) was assessed in a single centre observational pilot study in the current study.